H

Hwail Pharm Co Ltd
KOSDAQ:061250

Watchlist Manager
Hwail Pharm Co Ltd
KOSDAQ:061250
Watchlist
Price: 1 123 KRW 0.09% Market Closed
Market Cap: ₩97.2B

Net Margin

5.6%
Current
Improving
by 4.7%
vs 3-y average of 0.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
5.6%
=
Net Income
₩6.1B
/
Revenue
₩108.9B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
5.6%
=
Net Income
₩6.1B
/
Revenue
₩108.9B

Peer Comparison

Country Company Market Cap Net
Margin
KR
Hwail Pharm Co Ltd
KOSDAQ:061250
94.5B KRW
Loading...
US
Eli Lilly and Co
NYSE:LLY
992.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
541.8B USD
Loading...
CH
Roche Holding AG
SIX:ROG
270B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
218.4B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
151B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.9B EUR
Loading...

Market Distribution

In line with most companies in Korea
Percentile
69th
Based on 2 632 companies
69th percentile
5.6%
Low
-168 471.3% — -2.9%
Typical Range
-2.9% — 5.8%
High
5.8% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -2.9%
Median 1.9%
70th Percentile 5.8%
Max 21 012.5%

Hwail Pharm Co Ltd
Glance View

Market Cap
97.2B KRW
Industry
Pharmaceuticals

HWAIL PHARMACEUTICAL Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do and currently employs 149 full-time employees. The company went IPO on 2002-04-18. The firm produces aceclofenac, lornoxicam, triflusal, dicloalphenazone, gallamine triethyl iodide, acemetacin, levosulpiride, alibendol, erdostein, talniflumate, topiramate, phloroglucin, oxatomide and others used as expectorants, cough remedies, antispasmodics, analgesics, anti-inflammatories and others under the brand name EDST, TRPR, LVSP, ACCL and others. The company also provides finished formulations, including injection products such as ceftazidime, cefoperazone, cefotaxime, cefaclor, cefatrizine, cefroxadine and others. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
1 469.4 KRW
Undervaluation 24%
Intrinsic Value
Price
H
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
5.6%
=
Net Income
₩6.1B
/
Revenue
₩108.9B
What is Hwail Pharm Co Ltd's current Net Margin?

The current Net Margin for Hwail Pharm Co Ltd is 5.6%, which is above its 3-year median of 0.9%.

How has Net Margin changed over time?

Over the last 3 years, Hwail Pharm Co Ltd’s Net Margin has increased from 0% to 5.6%. During this period, it reached a low of -6.7% on Jun 30, 2023 and a high of 5.6% on Oct 30, 2025.

Back to Top